Gland Pharma Intrinsic Value
Gland Pharma (GLAND) median intrinsic value is ₹4626.00 from 9 valuation models (range ₹694–₹5783), vs current price ₹2313.00 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. Also explore GLAND share price data to track price trends across different timeframes.
GLAND Valuation Methods Summary — DCF, Graham Number & P/E
Gland Pharma intrinsic value across 9 models vs current price ₹2313.00 — upside/downside and value range per method. Browse Gland Pharma financial data for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹1958.88 | ₹1567.10 - ₹2350.66 | -15.3% | EPS: ₹89.04, Sector P/E: 22x |
| Book Value Method | asset | ₹5782.50 | ₹5204.25 - ₹6360.75 | +150.0% | Book Value/Share: ₹6092.94, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹4626.00 | ₹4163.40 - ₹5088.60 | +100.0% | Revenue/Share: ₹4362.35, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹4626.00 | ₹4163.40 - ₹5088.60 | +100.0% | EBITDA: ₹2500.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹5782.50 | ₹4626.00 - ₹6939.00 | +150.0% | CF Growth: 10.9%, Discount: 15% |
| PEG Ratio Method | growth | ₹693.90 | ₹624.51 - ₹763.29 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹1375.67 | ₹1238.10 - ₹1513.24 | -40.5% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹4626.00 | ₹4163.40 - ₹5088.60 | +100.0% | ROE: 14.2%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹3493.79 | ₹3144.41 - ₹3843.17 | +51.1% | EPS: ₹89.04, BVPS: ₹6092.94 |
GLAND Intrinsic Value vs Market Price — All Valuation Models
Gland Pharma fair value range ₹694–₹5783 vs current market price ₹2313.00 across 9 valuation models. For current market price and key ratios, visit Gland Pharma stock price NSE.
GLAND Intrinsic Value Analysis — Undervalued or Overvalued?
Gland Pharma median intrinsic value ₹4626.00, current price ₹2313.00 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.
What is the intrinsic value of GLAND?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Gland Pharma (GLAND) is ₹4626.00 (median value). With the current market price of ₹2313.00, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹693.90 to ₹5782.50, indicating ₹693.90 - ₹5782.50.
Is GLAND undervalued or overvalued?
Based on our multi-method analysis, Gland Pharma (GLAND) appears to be trading below calculated value by approximately 100.0%.
GLAND Financial Health — Key Ratios vs Industry Benchmarks
Gland Pharma financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 13.81 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 14.2% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 29.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.59x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
GLAND Cash Flow Quality — Operating & Free Cash Flow
Gland Pharma operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹915 Cr | ₹915 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹997 Cr | ₹123 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹364 Cr | ₹364 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹791 Cr | ₹292 Cr | Positive Free Cash Flow | 7/10 |
| March 2021 | ₹605 Cr | ₹-155 Cr | Positive Operating Cash Flow | 6/10 |